55 While intravitreal IL-6 monotherapy is helpful, 50% of patients have persistent IRF 1 , similar to the overall failure rate of systemic adalimumab, leaving room for a more potent and/or broader spectrum biologic therapy 1. Jaffe et al. N Engl J Med. 2016. 375:932-43. 2. Figure from Sharma, et al. A Novel Intravitreal Anti-IL-6 Monoclonal Antibody for Uveitic Macular Edema (UME): Preliminary Results From the Phase 1 DOVETAIL Study. Presented at the American Society of Retina Specialists, Seattle, WA, July 28 – August 1, 2023; Persistent intraretinal fluid (IRF) is known to cause permanent negative effects on visual function ~50% of patients have persistent IRF DOVETAIL Absence of IRF DOVETAIL Absence of SRF DOVETAIL ≥15-letter gainers at Week 12